AI assistant
Sending…
ARS Pharmaceuticals, Inc. — Director's Dealing 2020
Dec 4, 2020
32159_dirs_2020-12-03_528f9b5a-a2c4-41f9-b570-a4f96e4a3604.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-03
Reporting Person: Powell Andrew Kenneth William (Director)
More from ARS Pharmaceuticals, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 13
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5